Published in Transplantation on October 27, 2010
Is it time to prospectively match human leukocyte antigen proteins for lung transplantation? Transplantation (2010) 0.75
Influence of HLA Mismatching on Survival in Lung Transplantation. Lung (2015) 0.75
Pre-transplant Panel Reactive Antibody and Survival in Adult Cystic Fibrosis Patients After Lung Transplantation. Lung (2016) 0.75
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 3.25
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Multicenter analysis of kidney preservation. Transplantation (2007) 2.39
C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med (2009) 2.29
Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers. Transplantation (2014) 1.96
H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet (2008) 1.85
Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant (2005) 1.78
Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant (2003) 1.76
The effect of donor gender on graft survival. J Am Soc Nephrol (2002) 1.72
No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation (2011) 1.67
Pediatric kidney transplantation: analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma: a collaborative transplant study report. Transplantation (2010) 1.60
Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol (2007) 1.51
Prolongation of long-term kidney graft survival by a simultaneous liver transplant: the liver does it, and the heart does it too. Transplantation (2002) 1.48
Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int (2012) 1.47
Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation (2013) 1.36
Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant (2005) 1.18
Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation (2006) 1.11
Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers. Transplantation (2015) 1.05
No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol (2006) 1.05
Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation (2008) 1.04
Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation (2007) 1.03
Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. J Am Soc Nephrol (2008) 1.02
Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation (2009) 1.02
Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 1.01
Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation (2008) 1.00
Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation (2009) 0.99
Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome. Transplantation (2012) 0.99
Donor ABCB1 variant associates with increased risk for kidney allograft failure. J Am Soc Nephrol (2012) 0.98
Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation (2008) 0.97
Kidney transplantation across HLA and ABO antibody barriers. Curr Opin Organ Transplant (2013) 0.96
Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol (2009) 0.93
IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int (2012) 0.93
HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation (2009) 0.91
Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit (2010) 0.90
ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation (2012) 0.89
Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation. Transplantation (2010) 0.89
HLA matching and kidney transplantation: beyond graft survival. Clin Transpl (2013) 0.88
An integrative approach for the transplantation of high-risk sensitized patients. Transplantation (2010) 0.88
Genotypic diversity of complement component C4 does not predict kidney transplant outcome. J Am Soc Nephrol (2010) 0.86
Evaluation of T-cell receptor repertoires in patients with long-term renal allograft survival. Am J Transplant (2005) 0.86
Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int Immunopharmacol (2003) 0.84
Risks of allogeneic hand transplantation. Microsurgery (2004) 0.84
Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-γ and IL-2. Transplantation (2013) 0.84
The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period. Clin Transplant (2003) 0.83
Increased pretransplantation plasma kynurenine levels do not protect from but predict acute kidney allograft rejection. Hum Immunol (2010) 0.83
Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 0.82
Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis (2012) 0.82
Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. Transplantation (2015) 0.82
Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption. Transplantation (2015) 0.82
ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int (2005) 0.81
Transplantation of the type 1 diabetic patient: the long-term benefit of a functioning pancreas allograft. Clin J Am Soc Nephrol (2010) 0.81
Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study. Hum Immunol (2009) 0.81
The collaborative transplant study registry. Transplant Rev (Orlando) (2013) 0.81
Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Atheroscler Suppl (2013) 0.81
Expression of regulatory T-cell-related molecule genes and clinical outcome in kidney transplant recipients. Transplantation (2009) 0.81
Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol (2002) 0.81
Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation (2003) 0.81
VEGF 936 C/T gene polymorphism in renal transplant recipients: association of the T allele with good graft outcome. Hum Immunol (2007) 0.80
Serial peripheral blood interleukin-18 and perforin gene expression measurements for prediction of acute kidney graft rejection. Transplantation (2004) 0.80
Soluble CD30 as a predictor of kidney graft outcome. Transplantation (2002) 0.79
Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients. Transpl Int (2012) 0.79
Evaluation of hepatocyte growth factor as a sensitive marker for early detection of acute renal allograft rejection. Transplantation (2007) 0.79
Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood (2010) 0.79
Posttransplant sCD30 as a predictor of kidney graft outcome. Transplantation (2011) 0.79
Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft. Transpl Immunol (2011) 0.78
Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure. Hum Immunol (2012) 0.78
Association of mismatches for HLA-DR with incidence of posttransplant hip fracture in kidney transplant recipients. Transplantation (2011) 0.78
Pathway of apoptosis induced in Jurkat T lymphoblasts by anti-HLA class I antibodies. Hum Immunol (2004) 0.78
Influence of Current and Previous Smoking on Cancer and Mortality After Kidney Transplantation. Transplantation (2016) 0.78
Deleterious impact of mismatching for human leukocyte antigen-C in presensitized recipients of kidney transplants. Transplantation (2011) 0.77
Prevention of antibody-mediated kidney transplant rejection. Transpl Int (2012) 0.77
Deleterious impact of HLA-DRB1 allele mismatch in sensitized recipients of kidney retransplants. Transplantation (2013) 0.77
Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients. Transplantation (2015) 0.77
Does borderline kidney allograft rejection always require treatment? Transplantation (2010) 0.76
Induction of apoptosis in human lymphocytes by human anti-HLA class I antibodies. Transplantation (2003) 0.76
The role of pretransplant dialysis modality on renal allograft outcome. Nephrol Dial Transplant (2011) 0.76